In a report released yesterday, Andrew Tsai from Jefferies reiterated a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report), with a price target of $40.00. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback